BioCentury | Jul 10, 2018
Distillery Therapeutics

Dermatology

...cells and two cell lines with nonsense mutations in LAMB3, gentamicin increased expression of full-length LAMB3...
...with no treatment. Also in the cell lines, gentamicin increased levels of laminin 332, a LAMB3...
...and three other disease markers: hypermotility, poor growth and substratum adhesion. In a model of LAMB3...
BioCentury | Nov 30, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2017

...3 (LAMB3) Patient sample and cell culture studies suggest transplant of keratinocytes engineered to express LAMB3...
BioCentury | Nov 9, 2017
Preclinical News

LAMB3 gene therapy successfully treats epidermolysis bullosa

...engraftment of almost the entire epidermis of a patient with junctional epidermolysis bullosa (JEB) using laminin beta 3 (LAMB3)...
...genes encoding the basement membrane component laminin-332, and the 7-year-old patient had a mutation in LAMB3...
...created LAMB3 transgenic cultures of primary clonogenic cells and keratinocytes by retroviral transduction of full-length LAMB3...
BioCentury | Oct 12, 2017
Emerging Company Profile

Chemo-proof T cells

T cell therapies have shown unprecedented efficacy in hematologic malignancies, but haven’t produced the same results in solid tumors and have dangerous toxicities. By combining engineered, drug-resistant γδ T cells with chemotherapy, Incysus Ltd. has...
BioCentury | Apr 9, 2015
Distillery Therapeutics

Therapeutics: Triggering receptor expressed on myeloid cells 2 (TREM2)

Neurology INDICATION: Alzheimer's disease (AD) In vitro and mouse studies suggest inhibiting TREM2 could help treat AD. In two mouse models of AD, TREM2 was expressed on monocytes of peripheral origin that accumulate around β-amyloid...
BioCentury | May 30, 2013
Cover Story

RON's new role

A Utah team has shown that inhibiting the kinase RON could fight cancer metastasis by stimulating an antitumor immune response. 1 The findings build a case for directed drug discovery efforts against the target, which...
BioCentury | Apr 15, 2013
Company News

PPL, Roslin Institute other research news

PPL and Roslin scientists produced 5 transgenic sheep using their nuclear transfer procedure (see BioCentury Feb. 24). Fibroblasts cultured from Poll Dorset sheep were transfected with a gene encoding a human plasma protein or a...
BioCentury | Jul 23, 2012
Finance

In like a lion . . .

Human Genome Sciences Inc. (NASDAQ:HGSI) roared into biotech in the early 1990s with its genomics database. But it's going out like a lamb after GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) agreed to acquire the biotech last week...
BioCentury | May 24, 2012
Targets & Mechanisms

Getting selective for gamma

Cellzome AG and Exelixis Inc. have independently designed the first highly selective inhibitors of the g-isoform of phosphoinositide 3-kinase . 1,2 Exelixis plans to out-license its inhibitors, whereas last week's acquisition of Cellzome by GlaxoSmithKline plc...
BioCentury | Sep 22, 2011
Cover Story

Finding the repurpose

A Stanford University team has used a computational approach to analyze publicly available gene expression profiles and identified two drug repurposing opportunities. 1,2 The researchers found that the anticonvulsant topiramate could have use in inflammatory...
Items per page:
1 - 10 of 51